Analysts Offer Predictions for VERA FY2026 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Vera Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings of ($2.28) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $100.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share.

Several other research analysts have also recently issued reports on the company. Guggenheim reissued a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. JPMorgan Chase & Co. dropped their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $85.00 price target (up previously from $75.00) on shares of Vera Therapeutics in a research note on Monday, June 2nd. Finally, Wedbush lowered their price objective on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $65.00.

Vera Therapeutics Trading Up 1.0%

Shares of NASDAQ:VERA traded up $0.22 during trading on Wednesday, reaching $22.74. 1,306,850 shares of the company were exchanged, compared to its average volume of 946,038. The firm has a market capitalization of $1.45 billion, a PE ratio of -8.71 and a beta of 1.13. The business's fifty day simple moving average is $22.44 and its 200-day simple moving average is $30.92. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the prior year, the firm earned ($0.56) EPS.

Hedge Funds Weigh In On Vera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its stake in shares of Vera Therapeutics by 19.9% during the 4th quarter. California State Teachers Retirement System now owns 40,640 shares of the company's stock worth $1,719,000 after acquiring an additional 6,749 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Vera Therapeutics in the fourth quarter valued at about $2,948,000. Ameriprise Financial Inc. raised its stake in Vera Therapeutics by 31.7% in the fourth quarter. Ameriprise Financial Inc. now owns 30,021 shares of the company's stock valued at $1,270,000 after buying an additional 7,227 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Vera Therapeutics by 515.0% in the fourth quarter. Victory Capital Management Inc. now owns 235,267 shares of the company's stock worth $9,949,000 after acquiring an additional 197,014 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its stake in shares of Vera Therapeutics by 44.2% during the fourth quarter. Teacher Retirement System of Texas now owns 12,860 shares of the company's stock worth $544,000 after acquiring an additional 3,942 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.